# Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations

> **NCT06673290** · PHASE2,PHASE3 · RECRUITING · sponsor: **West China Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Lymphatic Malformation

## Interventions

- **DRUG:** Sirolimus (RAPAMUNE)

## Key facts

- **NCT ID:** NCT06673290
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673290, "Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06673290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*